Evidence map›Paper›PMID 41938102›Full record

ArticleESMO gastrointestinal oncology2026

Spatial immune profiling complements genomic sequencing in biliary tract cancer: hypothesis-generating use cases.

M Barsch, I Godbole, P Metzger, M Benzing, L Klaas, A Decker, A Dammer, J Weiß, E-P Dopfer, L Gräßel and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

M BarschClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
I GodboleClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
P MetzgerInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
M BenzingClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
L KlaasClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
A DeckerClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
A DammerClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J WeißDepartment of Diagnostic and Interventional Radiology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
E-P DopferComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
L GräßelComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J KuehnComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
C MiethingComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
H BeckerComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
S LassmannComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
P BronsertInstitute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
A M SchultheisComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
M WernerComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
M BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
J DuysterComprehensive Cancer Center Freiburg, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
R ThimmeClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
M HofmannClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
M QuanteClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
B BengschClinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology and Infectious Disease, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Personalized therapy approaches targeting homologous recombination deficiency (HRD) in biliary tract cancer (BTC) remain poorly explored with limited clinical data available. Beyond BRCA1/2, the therapeutic implications of BRCA1-associated protein 1 (BAP1) alterations are unclear. Materials and methods: We describe three patients with BTC and HRD-related mutations as hypothesis-generating use cases. We illustrate how integration of multiplexed imaging mass cytometry-based spatial immune profiling with genomic sequencing may help generate testable biological hypotheses beyond genomics alone. Results: A patient with germline Conclusion: These observations provide a rationale for integrated genomic and spatial immune profiling in BTC, which will require further prospective validation.

Indexed as

BAP1biliary tract cancerimaging mass cytometrymolecular tumor boardprecision oncologytumor immune microenvironment

Identifiers

PMID41938102
PMCPMC13049665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.